AAAAAA
Results: 76-100/3357
Authors:
Clark, MA
Blair, H
Liang, L
Brey, RN
Brayden, D
Hirst, BH
Citation: Ma. Clark et al., Targeting polymerised liposome vaccine carriers to intestinal M cells, VACCINE, 20(1-2), 2001, pp. 208-217
Authors:
Plante, M
Jones, T
Allard, F
Torossian, K
Gauthier, J
St-Felix, N
White, GL
Lowell, GH
Burt, DS
Citation: M. Plante et al., Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge, VACCINE, 20(1-2), 2001, pp. 218-225
Authors:
Zanetta, RAC
Amaku, M
Azevedo, RS
Zanetta, DMT
Burattini, MN
Massad, E
Citation: Rac. Zanetta et al., Optimal age for vaccination against measles in the State of Sao Paulo, Brazil, taking into account the mother's serostatus, VACCINE, 20(1-2), 2001, pp. 226-234
Authors:
Oliver, DC
Fernandez, RC
Citation: Dc. Oliver et Rc. Fernandez, Antibodies to BrkA augment killing of Bordetella pertussis, VACCINE, 20(1-2), 2001, pp. 235-241
Authors:
Green, TD
Newton, BR
Rota, PA
Xu, Y
Robinson, HL
Ross, TM
Citation: Td. Green et al., C3d enhancement of neutralizing, antibodies to measles hemagglutinin, VACCINE, 20(1-2), 2001, pp. 242-248
Authors:
Stittelaar, KJ
Hoogerhout, P
Ovaa, W
van Binnendijk, RRS
Poelen, MCM
Roholl, P
van Els, CACM
Osterhaus, ADME
Wiertz, EJHJ
Citation: Kj. Stittelaar et al., In vitro processing and presentation of a lipidated cytotoxic T-cell epitope derived from measles virus fusion protein, VACCINE, 20(1-2), 2001, pp. 249-261
Authors:
Huerta, M
de Aluja, AS
Fragoso, G
Toledo, A
Villalobos, N
Hernandez, M
Gevorkian, G
Acero, G
Diaz, A
Alvarez, I
Avila, R
Beltran, C
Garcia, G
Martinez, JJ
Larralde, C
Sciutto, E
Citation: M. Huerta et al., Synthetic peptide vaccine against Taenia solium pig cysticercosis: successful vaccination in a controlled field trial in rural Mexico, VACCINE, 20(1-2), 2001, pp. 262-266
Authors:
Min, WG
Lillehoj, HS
Burnside, J
Weining, KC
Staeheli, P
Zhu, JJ
Citation: Wg. Min et al., Adjuvant effects of IL-1 beta, IL-2, IL-8, IL-15, IFN-alpha, IFN-gamma TGF-beta 4 and lymphotactin on DNA vaccination against Eimeria acervulina, VACCINE, 20(1-2), 2001, pp. 267-274
Authors:
Aguiar, JC
Hedstrom, RC
Rogers, WO
Charoenvit, Y
Sacci, JB
Lanar, DE
Majam, VF
Stout, RR
Hoffman, SL
Citation: Jc. Aguiar et al., Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device, VACCINE, 20(1-2), 2001, pp. 275-280
Authors:
Linglof, T
van Hattum, J
Kaplan, KM
Corrigan, J
Duval, I
Jensen, E
Kuter, B
Citation: T. Linglof et al., An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA((R))) in adults: safety, tolerability, and immunogenicity (vol19, pg 3968, 2001), VACCINE, 20(1-2), 2001, pp. 281-281
Authors:
Aston, R
Citation: R. Aston, Analysis of factors influencing vaccine uptake from various perspectives, VACCINE, 20, 2001, pp. S1-S1
Authors:
Schmitt, HJ
Citation: Hj. Schmitt, Factors influencing vaccine uptake in Germany, VACCINE, 20, 2001, pp. S2-S4
Authors:
Swennen, B
Van Damme, P
Vellinga, A
Coppieters, Y
Depoorter, AM
Citation: B. Swennen et al., Analysis of factors influencing vaccine uptake: perspectives from Belgium, VACCINE, 20, 2001, pp. S5-S7
Authors:
Bonanni, P
Bergamini, M
Citation: P. Bonanni et M. Bergamini, Factors influencing vaccine uptake in Italy, VACCINE, 20, 2001, pp. S8-S12
Authors:
Alonso, JAN
Gonzalez, PJB
Carbonell, JCN
Citation: Jan. Alonso et al., Analysis of factors influencing vaccine uptake: perspective from Spain, VACCINE, 20, 2001, pp. S13-S15
Authors:
Plotkin, SA
Citation: Sa. Plotkin, Lessons learned concerning vaccine safety, VACCINE, 20, 2001, pp. S16-S19
Authors:
Verdier, F
Morgan, L
Citation: F. Verdier et L. Morgan, Predictive value of pre-clinical work for vaccine safety assessment, VACCINE, 20, 2001, pp. S21-S23
Authors:
Poolman, J
Berthet, FX
Citation: J. Poolman et Fx. Berthet, Alternative vaccine strategies to prevent serogroup B meningococcal diseases, VACCINE, 20, 2001, pp. S24-S26
Authors:
Openshaw, PJM
Culley, FJ
Olszewska, W
Citation: Pjm. Openshaw et al., Immunopathogenesis of vaccine-enhanced RSV disease, VACCINE, 20, 2001, pp. S27-S31
Authors:
Crowe, JE
Citation: Je. Crowe, Respiratory syncytial virus vaccine development, VACCINE, 20, 2001, pp. S32-S37
Authors:
Del Giudice, G
Podda, A
Rappuoli, R
Citation: G. Del Giudice et al., What are the limits of adjuvanticity?, VACCINE, 20, 2001, pp. S38-S41
Authors:
Glueck, R
Citation: R. Glueck, Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization, VACCINE, 20, 2001, pp. S42-S44
Authors:
Keller-Stanislawski, B
Citation: B. Keller-stanislawski, Feasibility of improving safety beyond certain limits in clinical trials, VACCINE, 20, 2001, pp. S45-S46
Authors:
Fritzell, B
Citation: B. Fritzell, Detection of adverse events: what are the current sensitivity limits during clinical development?, VACCINE, 20, 2001, pp. S47-S48
Statistical assessment of the association between vaccination and rare adverse events post-licensure
Authors:
Andrews, NJ
Citation: Nj. Andrews, Statistical assessment of the association between vaccination and rare adverse events post-licensure, VACCINE, 20, 2001, pp. S49-S53